S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
The Day of Financial Reckoning Is Near (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
The Day of Financial Reckoning Is Near (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
The Day of Financial Reckoning Is Near (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
The Day of Financial Reckoning Is Near (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
OTCMKTS:PKTX

ProtoKinetix - PKTX Stock Forecast, Price & News

$0.04
+0.01 (+29.41%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.04
$0.04
50-Day Range
$0.03
$0.05
52-Week Range
$0.02
$0.16
Volume
7,300 shs
Average Volume
108,243 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PKTX stock logo

About ProtoKinetix (OTCMKTS:PKTX) Stock

ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry-eye diseases. It has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Marietta, Ohio.

Receive PKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProtoKinetix and its competitors with MarketBeat's FREE daily newsletter.

PKTX Stock News Headlines

4 Penny Stocks Insiders Are Buying
News for ProtoKinetix IncShs
ProtoKinetix AAGP® Restores Vision in Blind Test Subjects
PKTX.PK - ProtoKinetix, Inc. Profile | Reuters
ProtoKinetix AAGP® Dry Eye Program Advancing
ProtoKinetix Stock
ProtoKinetix Inc.
See More Headlines
Receive PKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ProtoKinetix and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:PKTX
Previous Symbol
NASDAQ:PKTX
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Clarence Edward Smith (Age 58)
    Chairman, CEO & Pres
  • Mr. Michael Richard Guzzetta CPA (Age 64)
    Chief Financial Officer
    Comp: $60k
  • Dr. Jean-Charles Quirion Ph.D.
    Head of Researchers for Rouen













PKTX Stock - Frequently Asked Questions

How have PKTX shares performed in 2022?

ProtoKinetix's stock was trading at $0.10 on January 1st, 2022. Since then, PKTX stock has decreased by 56.0% and is now trading at $0.0440.
View the best growth stocks for 2022 here
.

Are investors shorting ProtoKinetix?

ProtoKinetix saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 17,200 shares, an increase of 300.0% from the July 15th total of 4,300 shares. Based on an average daily trading volume, of 85,300 shares, the days-to-cover ratio is currently 0.2 days.
View ProtoKinetix's Short Interest
.

What other stocks do shareholders of ProtoKinetix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ProtoKinetix investors own include Fulcrum Therapeutics (FULC), Rockwell Medical (RMTI), Provention Bio (PRVB), VIVUS (VVUS), Actinium Pharmaceuticals (ATNM), Chimerix (CMRX), Rexahn Pharmaceuticals (REXN), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

What is ProtoKinetix's stock symbol?

ProtoKinetix trades on the OTCMKTS under the ticker symbol "PKTX."

How do I buy shares of ProtoKinetix?

Shares of PKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ProtoKinetix's stock price today?

One share of PKTX stock can currently be purchased for approximately $0.04.

How can I contact ProtoKinetix?

ProtoKinetix's mailing address is 412 Mulberry St, MARIETTA, OH 45750-2016, United States. The official website for the company is www.protokinetix.com. The company can be reached via phone at (740) 434-5041.

This page (OTCMKTS:PKTX) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.